NSE: LAURUSLABS | BSE: 540222

Strong Performer, Getting Expensive

Download real time

701.80 21.45 (3.15%)

New 52W High today

3.4M NSE+BSE Volume

NSE 27 Jun, 2025 3:31 PM (IST)

37,884.9

Market Cap

High in industry

1.3

Beta 1Year

Very High Volatility

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Search Inside the pdf :

Laurus Labs Ltd.

20 May 2025

701.80

3.15%

Laurus Labs Ltd (Laurus) was incorporated in the year 2005 as an Anti-Retroviral (ARV) Active Pharmaceutical Ingredient (API) company. (ARV drugs are medications used to treat HIV infection and prevent its progression). Later, it diversified its operations by entering into Formulations and Contract Development Manufacturing Operations (CDMO) services to become an integrated pharma company. Currently, Laurus's...

Laurus Labs Ltd. has gained 65.30% in the last 1 Year

Laurus Labs Ltd.

30 Apr 2025

701.80

3.15%

Strong execution with positive Custom Synthesis outlook

Accumulate: Laurus Labs Ltd.

KRChoksey

Laurus Labs’ revenue for Q4FY25 stood at INR 17,203 Mn., up 19.5% YoY (+21.6% QoQ), which was above our estimates led by strong growth in Custom Synthesis segment.
Adj. EBITDA came in at INR 4,206 Mn., up 74.2% YoY (+47.5% QoQ), led by margin improvement of 768bps YoY (+430 bps QoQ) to 24.4%.

Laurus Labs Ltd. has gained 65.30% in the last 1 Year

Laurus Labs Ltd.

25 Apr 2025

701.80

3.15%

Laurus Labs (HOLD): Visibility of Operating Leverage

Hold: Laurus Labs Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 8.4%/32.6%/110.3%; EBITDA margin surpassed our estimate by 440 bps

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

24 Apr 2025

701.80

3.15%

FDF/CDMO drives earnings; ends FY25 on strong note

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered a second consecutive quarter with betterthan-expected performance, led by healthy traction in the Formulation (FDF)/API segment. Despite softer-than-expected performance in the CDMO business during 4QFY25, the quarterly sales run rate continued its uptrend.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

27 Jan 2025

701.80

3.15%

Late stage projects and high value API to drive growth

Accumulate: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs’ revenue beat our estimates significantly due to strong growth in Custom Synthesis segment and FDF segment. EBITDA beat our estimates due to better-than-expected gross profit and Adj. PAT beat our estimates due to strong operating performance.

Laurus Labs Ltd. has an average target of 649.60 from 5 brokers.

Laurus Labs Ltd.

27 Jan 2025

701.80

3.15%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

25 Jan 2025

701.80

3.15%

Beat on earnings; green shoots visible

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

25 Oct 2024

701.80

3.15%

Laurus Labs (SELL): Another weak quarter

Sell: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Earnings miss for 2Q on our and street estimates on all fronts. Revenue/PAT came short of consensus estimates by -5%/39%

Laurus Labs Ltd. has an average target of 649.60 from 5 brokers.

Laurus Labs Ltd.

25 Oct 2024

701.80

3.15%

Lower utilization and operating deleverage impacted profitability

Accumulate: Laurus Labs Ltd.

Recommendation Target

KRChoksey

Laurus Labs’ revenue missed our estimate due to weak demand in the Generic API segment. The profitability missed our estimates significantly due to operating deleverage and lower utilization.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

24 Oct 2024

701.80

3.15%

In-line quarter; CDMO traction to pick up in 2HFY25

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered largely in-line operational performance for 2QFY25. It witnessed an improving traction in the CDMO business, with a 33%/44% YoY/QoQ jump in sales for 2QFY25.

Laurus Labs Ltd. is trading above all available SMAs

Is Laurus Labs Ltd. worth buying?

1223 Votes:

Buy 79.64%

Sell 10.79%

Hold 9.57%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf